Adaptive Biotechnologies Corporation
ADPT
$17.46
$0.684.05%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 55.87% | 54.77% | 42.57% | 21.60% | 8.61% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 55.87% | 54.77% | 42.57% | 21.60% | 8.61% |
| Cost of Revenue | -0.98% | -5.66% | -8.66% | -12.59% | -13.75% |
| Gross Profit | 497.60% | 2,750.36% | 1,871.45% | 294.87% | 207.07% |
| SG&A Expenses | 11.57% | 6.16% | 1.43% | -2.50% | -8.87% |
| Depreciation & Amortization | 0.00% | -0.23% | -0.35% | -0.35% | -0.23% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.04% | -0.06% | -3.92% | -7.88% | -11.41% |
| Operating Income | 65.69% | 63.23% | 53.22% | 34.70% | 29.50% |
| Income Before Tax | 65.01% | 62.75% | 59.25% | 43.23% | 34.05% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 65.01% | 62.75% | 59.25% | 43.23% | 34.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -169.09% | -140.78% | -116.35% | -92.31% | -30.38% |
| Net Income | 64.97% | 62.69% | 59.22% | 43.21% | 34.05% |
| EBIT | 65.69% | 63.23% | 53.22% | 34.70% | 29.50% |
| EBITDA | 74.63% | 71.13% | 59.10% | 37.33% | 31.40% |
| EPS Basic | 66.29% | 63.63% | 60.03% | 44.49% | 35.36% |
| Normalized Basic EPS | 64.78% | 62.11% | 52.13% | 35.14% | 31.19% |
| EPS Diluted | 65.75% | 63.16% | 59.92% | 44.31% | 35.18% |
| Normalized Diluted EPS | 64.35% | 61.73% | 51.78% | 35.14% | 31.19% |
| Average Basic Shares Outstanding | 3.61% | 3.13% | 2.69% | 2.34% | 2.07% |
| Average Diluted Shares Outstanding | 5.42% | 4.96% | 4.52% | 2.34% | 2.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |